• Dr. Mark Stein, Principal Investigator of the first-in-man trial will discuss the first-in-human dose escalation study of oral ONC201 in advanced solid tumors at the 2015 ASCO Annual Meeting.

    ASCO-Poster_CINJ_ONC201_May-2015-3

     

Photostream